Contains fulltext : 81874.pdf (publisher's version ) (Closed access)BACKGROUND: Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive impairment (aMCI) without dementia, but the prevalence of AD pathology in patients with subjective cognitive impairment (SCI) and non-amnestic mild cognitive impairment (naMCI) is unknown. AD is characterised by decreased CSF concentrations of Abeta(42) and increased concentrations of tau. We investigated the prevalence of a CSF AD profile in patients with SCI, naMCI, or aMCI and the association of this profile with cognitive outcome in each group. METHODS: Patients with SCI, naMCI, aMCI, and neurologically healthy controls were recruited from 20 memory clinic...
INTRODUCTION: Clinical diagnosis of dementia requires cognitive evaluation, but CSF markers can be e...
Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (MCI) using b...
Objective: To study CSF biomarkers, beta-amyloid1-42 (Aβ1-42) and tau, and medial temporal lobe atro...
BACKGROUND: Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive im...
Background Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive imp...
Contains fulltext : 90105.pdf (publisher's version ) (Open Access)Decreased delaye...
Contains fulltext : 80451.pdf (publisher's version ) (Closed access)CONTEXT: Small...
Background: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) bioma...
OBJECTIVES: Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (...
Alzheimer’s disease · Dementia · Mild cognitive impairment Background: The clinical challenge in sub...
International audienceBackground: Few patients with a normal cerebrospinal fluid (CSF) biomarker pro...
Item does not contain fulltextBackground/Aims: To identify prodromal Alzheimer's disease (AD) subjec...
OBJECTIVE: To investigate if patterns of CSF biomarkers (T-tau, P-tau, and Abeta42) can predict cogn...
Objective: To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampa...
Objective: We assessed whether preclinical Alzheimer disease (AD) based on CSF biomarkers at baselin...
INTRODUCTION: Clinical diagnosis of dementia requires cognitive evaluation, but CSF markers can be e...
Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (MCI) using b...
Objective: To study CSF biomarkers, beta-amyloid1-42 (Aβ1-42) and tau, and medial temporal lobe atro...
BACKGROUND: Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive im...
Background Alzheimer's disease (AD) pathology is common in patients with amnestic mild cognitive imp...
Contains fulltext : 90105.pdf (publisher's version ) (Open Access)Decreased delaye...
Contains fulltext : 80451.pdf (publisher's version ) (Closed access)CONTEXT: Small...
Background: There is very limited data on the prevalence of abnormal cerebrospinal fluid (CSF) bioma...
OBJECTIVES: Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (...
Alzheimer’s disease · Dementia · Mild cognitive impairment Background: The clinical challenge in sub...
International audienceBackground: Few patients with a normal cerebrospinal fluid (CSF) biomarker pro...
Item does not contain fulltextBackground/Aims: To identify prodromal Alzheimer's disease (AD) subjec...
OBJECTIVE: To investigate if patterns of CSF biomarkers (T-tau, P-tau, and Abeta42) can predict cogn...
Objective: To compare the predictive accuracy of β-amyloid (Aβ)1-42 and total tau in CSF, hippocampa...
Objective: We assessed whether preclinical Alzheimer disease (AD) based on CSF biomarkers at baselin...
INTRODUCTION: Clinical diagnosis of dementia requires cognitive evaluation, but CSF markers can be e...
Alzheimer disease (AD) can now be diagnosed in subjects with mild cognitive impairment (MCI) using b...
Objective: To study CSF biomarkers, beta-amyloid1-42 (Aβ1-42) and tau, and medial temporal lobe atro...